| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Bioengineering,* University of Washington, Seattle, Washington; the Maine Medical Center Research Institute, Scarborough, Maine; and the Department of Anatomy and Cell Biology and Faculty of Dentistry, McGill University, Montreal, Quebec, Canada
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
1 to 2% of the elderly population.8
Although a common therapy for aortic stenosis is bioprosthetic tissue valve implantation, these replacement valves also suffer from ectopic mineralization, which is the leading cause of implant failure.9
In the kidney, renal stones affect millions yearly, and can lead to incapacitating pain as well as hydronephrosis and hydroureter.10 Recent insights into the mechanisms regulating ectopic calcification have predominantly come from studies of cardiovascular calcification. Similarities to bone mineralization were suggested by the finding that bone morphogenetic protein-2 and bone matrix proteins including osteopontin (OPN), osteonectin, osteocalcin, and matrix GLA protein are found in calcified vascular tissues.11 In addition, smooth muscle cells and other vascular media derived-cells demonstrate osteoblast-like properties and can mineralize their extracellular matrices under appropriate conditions in vitro.12-14 Moreover, ectopic bone formation has occasionally been found in calcified vascular lesions.15 Finally, matrix vesicles similar to those proposed to nucleate mineral in bone have been identified in calcified vascular tissues.16-18
Although these studies suggest cell-mediated regulation of ectopic mineralization, the most compelling data have come from studies of mutant mice. The matrix GLA protein-null mouse displays extensive calcification of the arterial tree, and animals die within 2 months apparently from aortic rupture.19 In addition, several other mutant mouse strains show enhanced susceptibility to ectopic calcification, including mice deficient in osteoprotegerin;20 ß-glucosidase; carbonic anhydrase II;21 desmin;22 fetuin;23 the progressive ankylosis gene, ANK;24 Npps, a nucleotide triphosphate pyrophosphohydrolase;25 and an intracellular mediator of transforming growth factor-ß signaling, Smad6.26 These findings highlight the fundamental importance and potential diversity of mechanisms that are genetically programmed in animals to prevent ectopic calcification.
One molecule that consistently co-localizes with ectopic calcification is OPN. OPN is an acidic phosphoprotein normally found in bone, teeth, kidney, and epithelial lining tissues. OPN's expression is increased under conditions of injury and disease in many tissues, and it is closely associated with the calcified deposits found in numerous pathologies including atherosclerotic lesions, aortic stenosis, kidney stones, and tumors.27 OPN is a multifunctional protein containing several structural domains including an integrin-binding (RGD) adhesive domain and aspartic acid-rich calcium-binding regions. In addition, OPN can be highly phosphorylated on serine and threonine residues. The combination of electronegative glutamic and aspartic acid residues, serine/threonine kinase substrate sites, and the putative calcium-binding motifs endow OPN with the ability to bind significant amounts of Ca2+ (50 mol calcium to 1 mol osteopontin).28 These properties likely contribute to OPN's ability to bind and regulate apatite crystal growth, the predominant calcium-phosphate mineral phase found in bones and teeth as well as at sites of ectopic calcification. Indeed, in vitro studies support a role for OPN as an inhibitor of apatite growth in both cell-free and cell-dependent in vitro models.13,29-31 On the other hand, the co-localization of OPN with biomineralization in hard tissues, and its ability to bind and potentially orient calcium suggest that OPN might function to promote calcification in vivo.32 To determine the role of OPN in ectopic calcification, we developed a model of ectopic calcification in OPN-replete and -deficient mice. Our studies indicate that OPN is a potent inhibitor of ectopic calcification, and suggest a novel function for OPN in controlling mineral-dissolving inflammatory cell function at sites of ectopic calcification.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
OPN mutant mice were generated in a 129/SvJ X Black Swiss background and genotyped as previously described by Liaw and colleagues.33 Animals were maintained in a specific pathogen-free environment, and fed standard chow and water ad libitum. Hybrid mutant mice were backcrossed onto the Black Swiss background for >7 generations. OPN homozygous wild-type (+/+), heterozygote (+/-), and homozygous null mice on the fixed Black Swiss background were used in these studies. Porcine aortic valve leaflets (kindly provided by St. Jude Medical, Inc., Minneapolis, MN) were aseptically dissected from porcine aortic valves obtained from the local abattoir, fixed in 0.6% glutaraldehyde in phosphate-buffered saline (PBS), pH 7.4, and stored in 0.6% glutaraldehyde in PBS, pH 7.4 until use. Four-mm2 biopsy punches of glutaraldehyde-fixed aortic valve leaflets (GFAVs) were prepared, washed extensively in sterile PBS, and subcutaneously implanted into the dorsal side of anesthetized 5- to 6-week-old, female OPN +/+, +/-, or -/- mice (two GFAVs per mouse). At the indicated times, mice were euthanized, and implants removed for either histological analysis or calcium quantitation. All protocols were approved by the animal use committee, University of Washington, Seattle, WA.
Histological Analysis
Explants were fixed with methyl Carnoy’s solution (3:1, methanol:acetic acid) and embedded in paraffin. Immunostaining was performed in 5-µm sections with goat anti-rat OPN antibody (OP199)34 at 10 µg/ml, macrophage-specific rat anti-mouse BM-8 (Accurate Chemical & Scientific Corp., Westbury, NY) at 6 µg/ml, or sheep anti-human carbonic anhydrase II (CAII) (Biodesign International, Kennebunk, ME) at 5 µg/ml, and counterstained with methyl green as previously described.35 Calcium phosphate deposition was visualized by Alizarin Red S staining and von Kossa staining.36 Transmission electron microscopy was performed as described by Wada and colleagues.13
Image Analysis
Four to 8 OPN+/+, +/- and -/- mice were subcutaneously implanted with two GFAVs as described above. At each time point, implants and adherent host tissues were retrieved, fixed, and embedded as described above. For each recovered specimen (two per mouse), two histological sections were prepared at least 50 µm apart, for a total of four sections per animal. OPN, BM-8, and CAII staining in sections was performed as described above and quantitated using the ProImage Analysis Program. The area containing the GFAV implant and the associated foreign body capsule was circumscribed and the percentage of this area stained with each antibody determined and averaged to generate the percent area stained per implant per mouse. The percent area stained per implant per mouse for four to eight mice were averaged to obtain the average percent area stained for each genotype ± SE.
Calcium Quantitation
Explants were freeze-dried to constant weight and decalcified with 0.6 N HCl overnight at room temperature. Calcium quantitation was performed by the o-cresolphthalein complexone as directed in the Sigma Diagnostic kit (Sigma, St. Louis, MO) and normalized to dry weight, as previously described.13 Accuracy of the kit was confirmed by atomic absorption spectroscopy (kindly performed by Baxter Health Care Corporation, Irvine, CA).
GFAV Explant pH Analysis
GFAV explants were freeze-dried then immersed in Universal Indicator Solution (Fisher Scientific, Pittsburgh, PA). The pH of the GFAV solution was determined by three different, blinded readers by comparing the color of this solution to the manufacturer’s provided graded color scale. Accuracy of the color indicator solution was determined using an MI-408 needle pH microelectrode (Microelectrodes, Inc., Bedford, NH). Control experiments indicated that tissue lyophilization did not significantly alter pH of GFAV using either the dye or microelectrode measurement method (data not shown).
Cell Culture and Western Blot Analysis
HL-60 cells (American Type Culture Collection, Rockville, MD) were maintained in RPMI media (Life Technologies, Inc., Grand Island, NY) containing 5% fetal bovine serum, 100 U/ml penicillin (Life Technologies, Inc.), and 100 mg/ml streptomycin (Life Technologies, Inc.). Primary human monocytes were differentially isolated from human blood,37,38 and maintained in RPMI containing 5% autologous human serum. Preparation of protein extracts, gel electrophoresis, and Western blotting were performed as previously described39 using 5 µg/ml of sheep anti-human CA II (Biodesign International, Kennebunk, ME).
Statistical Analysis
Data were analyzed for statistical significance using analysis of variance statistics with Fischer’s protected least significance difference test. Calculations were performed using the computer program StatView version 4.11 (Abacus Concepts, Berkeley, CA).
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Four-mm2
pieces of GFAV were subcutaneously implanted into mice carrying either the OPN homozygous wild-type (OPN+/+), heterozygous (OPN+/-), or homozygous null (OPN-/-) alleles.33
At 7, 14, 30, and 90 days, implants were removed and assayed for mineral deposition, protein accumulation, and cell recruitment. In all animals, a robust foreign body response was induced by GFAV implantation. This host response was characterized by accumulation of macrophages, formation of giant cells, and fibrous encapsulation by days 14 and 30 (Figure 1; A to C
). There were no obvious differences in quantity of the foreign body response between the different genotypes as determined by hematoxylin and eosin staining (Figure 1; A to C
and data not shown), and this response was similar to the foreign body response typically observed after GFAV implantation in rats40
and rabbits.41
However, differences in the quality of the foreign body response, especially in terms of macrophage number, was noted between genotypes as described below.
|
, OPN was highly expressed in host cells surrounding the GFAV implant in OPN+/+ mice at days 14 and 30. In contrast, OPN+/- mice showed little OPN staining at day 14 (Figure 1G)
, even when examined at high magnification (data not shown), but showed marked accumulation at day 30 (Figure 1H)
. Staining of adjacent sections with macrophage-specific marker, BM-8 (not shown), indicated that cells expressing OPN were predominantly of macrophage origin, and included a subset of mononuclear macrophages as well as multinucleated giant cells (Figure 1F)
. In addition, punctate OPN staining was also observed within the GFAV implant itself, especially in the 30-day OPN+/+ mice (Figure 1, E and F)
. This staining was co-localized with GFAV mineral deposits as determined by alizarin red staining of an adjacent section (data not shown, as well as the double-staining experiment shown in Figure 3, G and H
, described in detail below). Levels of OPN associated with GFAV increased in OPN+/+ and OPN+/- mice with increasing time of implantation (Figures 1 and 2A)
. As expected, no OPN was detected in OPN-/- mice at any time point examined (Figures 1I and 2A)
.
|
|
, alizarin red S staining (Figure 3)
, and von Kossa staining (not shown). None of the mice showed significant calcification at day 7. This did not appear to be because of a sensitivity problem, as we were unable to detect calcification using the sensitive fluorescent stain, calcein, in these samples (data not shown). Low levels of calcification were observed in GFAV implants at day 14 and day 30 in OPN+/+ mice (Figure 2B
and Figure 3, A and B
), and these levels were not statistically different. In contrast, significant calcification was observed in both OPN+/- and OPN-/- mice at day 14, at levels fourfold to fivefold greater than that observed at day 14 in OPN+/+ mice (Figure 2B
and Figure 3, C and E
). Finally, it did not appear that calcification was restricted to the OPN-deficient mice, as GFAVs implanted for 90 days in OPN wild-type mice showed considerable calcification, although still less than OPN null mice (OPN+/+ = 3000 ± 600 mmol Ca/L/g protein versus OPN+/- = 1900 ± 500 mmol Ca/L/g protein versus OPN-/- = 6900 ± 250 mmol Ca/L/g protein). Hence, these studies indicate that OPN plays a role in modulating GFAV calcification in vivo.
As shown in Figure 3
, calcium deposits visualized by alizarin red staining were deposited along the periphery as well as throughout the interior of the implant. Calcification occurred predominantly in foci within the GFAV leaflet. OPN, in addition to being localized to cells of the foreign body reaction, was found associated with these punctate-mineralized deposits within the GFAV implant as shown by double staining with antibody to OPN and alizarin red S for mineral (Figure 3, G and H)
. By transmission electron microscopy, the foci of mineralization within the GFAV implant were found to be associated predominantly with cell remnants including membranous debris resembling matrix vesicles (Figure 4)
. This localization is consistent with reports describing experimental and patient GFAV mineralization on remnant cell membranes and organelles.42-44
Taken together, these studies implicate OPN, most likely derived from infiltrating macrophages and giant cells, as an inhibitor of ectopic calcification in this model system. Co-localization of OPN protein with mineralization within the GFAV suggest that OPN binding to nascent sites of mineralization may be one mechanism by which OPN exerts its anti-calcific effect.
|
Comparison of calcification with OPN levels in GFAV at day 14 after implantation indicated that OPN was an inhibitor of ectopic calcification. These findings are consistent with previous in vitro studies showing that OPN can bind to and block hydroxyapatite crystal growth.29
However, examination of the OPN mutants at day 30 after implantation suggested that simple physical inhibition alone could not explain the inhibitory effect of OPN on ectopic calcification in this model system. By 30 days, significant levels of OPN accumulated in OPN+/- mice throughout the GFAV implant and was similar to levels observed in OPN+/+ mice (Figure 2A
, and immunostaining data not shown). Strikingly, OPN accumulation in OPN+/- mice at day 30 was concurrent with a significant reduction in GFAV mineralization from the levels observed at day 14 (Figure 2B
and Figure 3, C and D
). If OPN acted simply as a crystal poison, one would expect little difference in the day 14 and day 30 calcification values after implant in the OPN+/- mice. Thus, these findings suggested that OPN additionally acted to promote regression of ectopic calcification.
Macrophage Number and Phagocytosis Do Not Correlate with Extent of Mineralization in GFAV Implants in OPN Mutant Mice
Because OPN binding alone cannot mediate the dissolution of calcium phosphate, we hypothesized that the observed mineral regression was the result of an OPN-regulated cell-mediated dissolution of mineral. The only known mechanisms capable of removing calcium phosphate crystals are phagocytosis and acidification.45
To address the former possibility, we examined macrophage accumulation in our model. In all genotypes and time points examined, BM-8-positive cells accumulated in the foreign body reaction, preferentially along the edge of the GFAV implant (Figure 5; A to C
, and data not shown). However, few, if any, macrophages were able to penetrate the GFAV at any time point examined (Figure 5; D to F
, and data not shown). This is consistent with previous studies demonstrating the effect of glutaraldehyde fixation in blocking tissue degradation, and is one of the main reason that glutaraldehyde crosslinked valves are used clinically.46
Because macrophages were unable to enter the GFAV, phagocytosis of mineral deposits within the implant is unlikely to account for the observed mineral loss in heterozygous mice.
|
, OPN-/- mice demonstrated BM-8-positive cell staining, but at levels 50 to 25% lower than OPN+/+ at 14 and 30 days of implantation, respectively. Although OPN+/- mice also had lower BM-8-positive cell accumulation at day 30, levels were not significantly different from those observed in OPN +/+ mice at day 14. Thus, total macrophage levels did not correlate with the mineral loss pattern observed in the OPN+/- mice between day 14 and at day 30 (compare Figure 2B
and Figure 6
). Therefore, it seemed unlikely that the loss of mineral was strictly regulated by macrophage number alone.
|
These findings led us to investigate whether OPN promotes implant acidification. The ability of cells to dissolve calcium phosphate mineral by promoting local decreases in pH has been described for both macrophages and osteoclasts.41
Osteoclasts and macrophages are derived from a similar hematopoietic origin, and previous reports suggest multinucleated osteoclasts can be produced from the fusion of monocytes or macrophages. To test the acidification hypothesis, GFAVs were explanted from OPN+/+, OPN+/-, and OPN-/- mice after 14 days of implantation, and pH determined using Fisher’s universal indicator solution (a mixture of pH sensitive dyes including phenolphthalein, bromothymol blue, methyl red, and thymol). As shown in Figure 7
, GFAV explants from OPN+/+ mice at 2 weeks had an acidic pH (pH 6.0), whereas explants from OPN-/- mice were more neutral (pH 6.7). These differences in pH were highly statistically significant (P = 0.0002), and confirmed using a needle microelectrode in a second set of GFAV valves (data not shown). GFAV explants from OPN+/- mice were intermediate with respect to those from OPN+/+ and OPN-/- mice with pH 6.2. Because apatite stability is low at pH less than 7 at 37°C,49
the observed pH of the explants would be physiologically relevant with respect to ability to dissolve apatitic mineral and could explain the observed loss in GFAV mineralization. These findings strongly suggest that OPN regulates the ability of host cells to acidify the GFAV microenvironment, thereby controlling mineral dissolution.
|
To shed light on the mechanism by which OPN might mediate GFAV acidification, we examined levels of CAII in the cells surrounding the implants. CAII is an enzyme that promotes the conversion of carbon dioxide to carbonic acid. In osteoclasts, CAII-driven carbonic acid production serves as an intracellular source of protons that are exported from the cell via a vacuolar H+-ATPase thereby reducing local pH, and promoting mineral dissolution.50
To evaluate the acid-producing potential of cells recruited to the GFAV implant, we examined the presence of CAII immunohistochemically. CAII was strongly expressed by a subset of BM-8-positive mononuclear cells (arrowheads) as well as all multinucleated giant cells (arrows) located within the foreign body response adjacent to the mineralized implant (Figure 8, A and B)
. Although the giant cells resembled osteoclasts in being multinucleated and expressing high levels of OPN, 
vß3, and cathepsin K, no characteristic clear zones or ruffled borders were observed by electron microscopy (Figure 8B
and data not shown).
|
. At this time point, CAII levels were low in OPN +/+ mice (Figure 9)
. At 30 days, when GFAV mineralization increased and OPN levels accumulated in OPN +/+ mice (Figure 3)
, CAII-expressing cells were dramatically increased (Figure 7B)
. Conversely, the OPN-/- mice expressed very low CAII levels despite the elevated mineral levels at all observed time points. The OPN-mediated CAII response appeared accelerated in the OPN+/- mice. At 14 days, OPN+/- mice demonstrated substantial GFAV mineralization and low levels of OPN (Figure 2)
, but appeared to be able to respond to the mineralization by producing CAII-positive cells (Figure 9)
.
|
, OPN induced CAII protein expression in both cell types. This activity was mimicked by the addition of the vß3-crosslinking antibody, LM609, to HL60 cells.52
Furthermore, RGD peptides inhibited the ability of OPN to induce CAII expression in primary human monocyte-derived macrophages (data not shown). These findings support the hypothesis that OPN promotes acidification by vß3-mediated CAII induction and subsequent proton production in monocytic cells.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
To determine the function of OPN in vivo, we developed a subcutaneous GFAV implantation model in the mouse. In this model, bioapatites were deposited throughout the GFAV implant with time. By electron microscopy, crystals appeared to nucleate and grow early within residual cell bodies and membrane-bound vesicular cell fragments resembling matrix vesicles. OPN was expressed by monocyte-derived macrophages and giant cells in the surrounding foreign body response, and accumulated at foci of mineralization within the implants. These findings are consistent with observations made in GFAV implantation models in rats and rabbits.40,41,53
Although accelerated, all of these models mimic the human pathology observed during native and bioprosthetic aortic valve failure both in levels of mineral deposition (100 µg calcium/mg tissue), presence of inflammation, and OPN accumulation.54,55
In fact, the subcutaneous implantation model in rats and rabbits has become a standard preclinical animal model used to analyze the effectiveness of potential bioprosthetic valve anti-calcific agents.53
Using the GFAV subcutaneous model in mice bearing targeted deletion of the OPN gene, we show that OPN is a potent, endogenous inhibitor of ectopic calcification. OPN levels in mutant mice were inversely proportional to calcification levels. OPN-/- mice showed not only more GFAV calcification at all time points studied, but they also became calcified at earlier time points than OPN+/+ or OPN+/- mice. These findings are consistent with previous in vitro studies showing that OPN inhibits hydroxyapatite growth in solution and in calcifying smooth muscle cell cultures.13,29,30 In those studies, OPN was found to bind tightly to hydroxyapatite, suggesting that it acted as a physical inhibitor of crystal growth by binding to growing crystal faces. Evidence for this mechanism was seen in our studies as OPN was found to co-localize with mineral deposits within the calcifying GFAVs. However, our studies also provide new mechanistic insights into the role of OPN in controlling ectopic calcification that could not be predicted based on the in vitro findings. Although significant calcification was observed in GFAVs in OPN+/- mice at 2 weeks, by 4 weeks calcification had regressed to levels observed in wild-type mice. This decrease in calcification correlated with an increase in OPN accumulation between 2 and 4 weeks in GFAVs of OPN+/- mice. These data indicate that OPN does not merely physically inhibit ectopic calcification, but promotes dissolution as well.
How does OPN promote regression of GFAV calcification? Our studies indicate that OPN contributes to the regulation of pH in the implant environment. We found that OPN-/- mice, and to a lesser extent, OPN+/- mice, were defective in their ability to acidify the GFAV implants when compared to OPN+/+ mice. Because bioapatites are unstable below pH 7 at body temperature,45 this failure to acidify likely contributes to the increased mineralization observed in OPN-/- mice. Furthermore, OPN regulation of implant pH could explain the reversal of calcification observed between 2 and 4 weeks in OPN+/- mice, because OPN levels accumulate almost to wild-type levels in OPN+/- mice by 4 weeks.
We were able to measure pH differences within the microenvironment of the GFAVs because of the encapsulation caused by the foreign body reaction that follows GFAV implantation. Avascular foreign body capsules such as those observed in our studies are well known to essentially wall off the foreign body, thereby isolating the implants physically and chemically from the surrounding host tissues.56 Such encapsulation of foreign bodies is thus a major problem in the development of blood chemistry-sensing devices such as glucose sensors.57 Thus, what is typically considered a detrimental foreign body response enabled us to monitor pH within the microenvironment of the GFAV implant in these studies. Finally, the finding that macrophage levels as well as the ability of macrophages and giant cells to express CAII were dependent on OPN genotype indicates that OPN may be involved in regulating the foreign body reaction in general.
To determine the mechanism by which OPN might regulate implant acidity, we examined CAII levels in cells surrounding the GFAV implant. CAII is found in most cells, but is highly expressed in osteoclasts, the major mineral resorbing cell in the body. CAII enzymatically converts carbon dioxide to carbonic acid. In osteoclasts, CAII-driven carbonic acid production serves as an intracellular source of protons that are exported from the cell via a vacuolar H+-ATPase thereby reducing local pH, and facilitating mineral dissolution.50
Furthermore, CAII deficiency in humans and mice leads to soft tissue calcifications, in addition to osteopetrosis.21
We found that CAII was expressed in a subset of macrophages, as well as most giant cells, associated with the foreign body response to GFAV implants. Although the giant cells resembled osteoclasts by being multinucleated and expressing high levels of OPN, CAII, vß3, and cathepsin K, no structures resembling clear zones or ruffled borders characteristic of actively resorbing osteoclasts were observed. Thus, these cells represent a previously uncharacterized cell type that may be particularly important for resorption of ectopic mineralization.
We found that CAII expression in macrophages and multinucleated giant cells surrounding the GFAV implants correlated with two parameters: OPN levels and presence of mineral in the implant. These data suggest that OPN localization to bioapatite within the implant may be required for localized up-regulation of CAII levels in adjacent macrophages/giant cells. In support of a direct effect of OPN on CAII expression, we found that OPN induced CAII protein levels in monocytic HL60 as well as primary human peripheral blood-derived macrophages. Furthermore, the effect of OPN on CAII expression in HL-60 cells was mimicked by an vß3 crosslinking antibody (LM609), and blocked by RGD peptides (data not shown), suggesting that OPN may act through vß3 to control CAII expression in monocytic cells.
These findings have led us to propose a new, dual model for OPN function in regulating ectopic calcification (Figure 11)
. According to this model, OPN, elaborated by stromal or inflammatory cells at sites of ectopic mineralization, binds to bioapatites and initially physically inhibits crystal growth. Binding of OPN to bioapatite simultaneously provides a recognition site and/or concentration gradient for macrophages and giant cells thereby leading to localized accumulation and up-regulation of CAII, increased proton efflux, and acidification of the local microenvironment. Local acidification would then lead to dissolution of residual bioapatite. Although our studies support this model and indicate that OPN may directly interact with monocytic cell to induce CAII expression and proton release via a receptor mediated pathway, further studies are needed to definitively show that this mechanism is operative during regression of GFAV implant calcification, or other types of ectopic mineralization, in vivo. Finally, OPN promotes receptor-mediated recruitment and migration of additional macrophages, thereby further enhancing mineral regressive mechanisms.
|
vß3 receptors on osteoclasts,60
and is thought to play a role in initial osteoclast recognition and attachment to bone.61
Indeed, OPN promotes cytoskeletal rearrangements62
as well as osteoclast differentiation63
necessary for osteoclastic resorption in vitro, and OPN-/- mice display a deficit in bone resorption after ovariectomy,64
mechanical unloading,65
and PTH treatment.66
Although vß3 is known to regulate osteoclastic resorption,67
the mechanisms by which vß3 facilitates this process are still under investigation. Given these similarities, it is interesting to speculate that control of CAII may also be involved in OPN/vß3-mediated osteoclastic bone resorption.
Finally, our findings are among the first to provide evidence that regression of ectopic calcification can occur in vivo. Consistent with this idea, osteoclast-like cells have been detected in mineralized atherosclerotic lesions,68
native cardiac valves,69
and bioprosthetic valves.70
Of particular interest, a recent study of 102 symptomatic patients with coronary vascular calcification found that 15% of patients showed evidence of regression of calcification based on electron beam computed tomography (EBCT) calcium scores measured at baseline and 6 months later.71
Along with our findings, these studies suggest provocative new physiological mechanisms controlling ectopic mineralization and suggest novel therapeutic approaches in treating and perhaps reversing ectopic calcification.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by the National Institutes of Health (training grant GM07037 to S. A. S. and grant IRO1 HL62329-01 to C. M. G.), the University of Washington Engineered Biomaterials National Science Foundation (grant EEC9529161 to C. M. G.), and the Medical Research Council (grant MT11360 to M. D. M.).
M. D. M. is a member of the Medical Research Council of Canada Group in Periodontal Physiology, and a scholar of the Fellow of the Royal Society of Quebec.
Accepted for publication August 19, 2002.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Related articles in Am J Pathol:
This article has been cited by other articles:
 |
|
 |
|
  M. A. Guerraty, G. R. Grant, J. W. Karanian, O. A. Chiesa, W. F. Pritchard, and P. F. Davies Hypercholesterolemia Induces Side-Specific Phenotypic Changes and Peroxisome Proliferator-Activated Receptor-{gamma} Pathway Activation in Swine Aortic Valve Endothelium Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 225 - 231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, M. Y. Speer, H. Yang, J. Bergen, and C. M. Giachelli Vitamin D Receptor Activators Induce an Anticalcific Paracrine Program in Macrophages: Requirement of Osteopontin Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 321 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Delhon, S. Gutzwiller, F. Morvan, S. Rangwala, L. Wyder, G. Evans, A. Studer, M. Kneissel, and B. Fournier Absence of Estrogen Receptor-Related-{alpha} Increases Osteoblastic Differentiation and Cancellous Bone Mineral Density Endocrinology, October 1, 2009; 150(10): 4463 - 4472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Koshikawa, K. Aizawa, H. Kasai, A. Izawa, T. Tomita, S. Kumazaki, H. Tsutsui, J. Koyama, S. Shimodaira, M. Takahashi, et al. Elevated Osteopontin Levels in Patients With Peripheral Arterial Disease Angiology, February 1, 2009; 60(1): 42 - 45. [Abstract] [PDF]
|
|
|
|
 |
|
 F. J. Schoen Evolving Concepts of Cardiac Valve Dynamics: The Continuum of Development, Functional Structure, Pathobiology, and Tissue Engineering Circulation, October 28, 2008; 118(18): 1864 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Demer and Y. Tintut Vascular Calcification: Pathobiology of a Multifaceted Disease Circulation, June 3, 2008; 117(22): 2938 - 2948. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Towler Vascular Calcification: A Perspective On An Imminent Disease Epidemic IBMS BoneKEy, February 1, 2008; 5(2): 41 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Al-Aly, J.-S. Shao, C.-F. Lai, E. Huang, J. Cai, A. Behrmann, S.-L. Cheng, and D. A. Towler Aortic Msx2-Wnt Calcification Cascade Is Regulated by TNF-{alpha} Dependent Signals in Diabetic Ldlr / Mice Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2589 - 2596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Scatena, L. Liaw, and C. M. Giachelli Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2302 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Liu, V. R. Joag, and A. I. Gotlieb The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve Pathobiology Am. J. Pathol., November 1, 2007; 171(5): 1407 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Westenfeld, C. Schafer, R. Smeets, V. M. Brandenburg, J. Floege, M. Ketteler, and W. Jahnen-Dechent Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1537 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Kaartinen, M. Murshed, G. Karsenty, and M. D. McKee Osteopontin Upregulation and Polymerization by Transglutaminase 2 in Calcified Arteries of Matrix Gla Protein-deficient Mice J. Histochem. Cytochem., April 1, 2007; 55(4): 375 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Meng, I. Vera, N. Che, X. Wang, S. S. Wang, L. Ingram-Drake, E. E. Schadt, T. A. Drake, and A. J. Lusis Identification of Abcc6 as the major causal gene for dystrophic cardiac calcification in mice through integrative genomics PNAS, March 13, 2007; 104(11): 4530 - 4535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Clark-Greuel, J. M. Connolly, E. Sorichillo, N. R. Narula, H. S. Rapoport, E. R. Mohler III, J. H. Gorman III, R. C. Gorman, and R. J. Levy Transforming Growth Factor-{beta}1 Mechanisms in Aortic Valve Calcification: Increased Alkaline Phosphatase and Related Events Ann. Thorac. Surg., March 1, 2007; 83(3): 946 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Shetty, A Pepin, A Charest, J Perron, D Doyle, P Voisine, F Dagenais, P Pibarot, and P Mathieu Expression of bone-regulatory proteins in human valve allografts Heart, September 1, 2006; 92(9): 1303 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien Pathogenesis of Calcific Aortic Valve Disease: A Disease Process Comes of Age (and a Good Deal More) Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): 1721 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Shao, J. Cai, and D. A. Towler Molecular Mechanisms of Vascular Calcification: Lessons Learned From The Aorta Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1423 - 1430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-F. Lai, V. Seshadri, K. Huang, J.-S. Shao, J. Cai, R. Vattikuti, A. Schumacher, A. P. Loewy, D. T. Denhardt, S. R. Rittling, et al. An Osteopontin-NADPH Oxidase Signaling Cascade Promotes Pro-Matrix Metalloproteinase 9 Activation in Aortic Mesenchymal Cells Circ. Res., June 23, 2006; 98(12): 1479 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ketteler, G. Schlieper, and J. Floege Calcification and Cardiovascular Health: New Insights Into an Old Phenomenon Hypertension, June 1, 2006; 47(6): 1027 - 1034. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Shanahan Vascular calcification--a matter of damage limitation? Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1166 - 1169. [Full Text] [PDF]
|
|
|
|
|
|
R. Essalihi, H. H. Dao, L.-A. Gilbert, C. Bouvet, Y. Semerjian, M. D. McKee, and P. Moreau Regression of Medial Elastocalcinosis in Rat Aorta: A New Vascular Function for Carbonic Anhydrase Circulation, September 13, 2005; 112(11): 1628 - 1635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Seipelt, C. L. Backer, C. Mavroudis, V. Stellmach, M. Cornwell, I. M. Seipelt, F. A. Schoendube, and S. E. Crawford Local delivery of osteopontin attenuates vascular remodeling by altering matrix metalloproteinase-2 in a rabbit model of aortic injury J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hamerman Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies QJM, July 1, 2005; 98(7): 467 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.D.M. Collett and A.E. Canfield Angiogenesis and Pericytes in the Initiation of Ectopic Calcification Circ. Res., May 13, 2005; 96(9): 930 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Dao, R. Essalihi, C. Bouvet, and P. Moreau Evolution and modulation of age-related medial elastocalcinosis: Impact on large artery stiffness and isolated systolic hypertension Cardiovasc Res, May 1, 2005; 66(2): 307 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Speer, Y.-C. Chien, M. Quan, H.-Y. Yang, H. Vali, M. D. McKee, and C. M. Giachelli Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro Cardiovasc Res, May 1, 2005; 66(2): 324 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Giachelli, M. Y. Speer, X. Li, R. M. Rajachar, and H. Yang Regulation of Vascular Calcification: Roles of Phosphate and Osteopontin Circ. Res., April 15, 2005; 96(7): 717 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Towler Inorganic Pyrophosphate: A Paracrine Regulator of Vascular Calcification and Smooth Muscle Phenotype Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 651 - 654. [Full Text] [PDF]
|
|
|
|
|
|
K. Johnson, M. Polewski, D. van Etten, and R. Terkeltaub Chondrogenesis Mediated by PPi Depletion Promotes Spontaneous Aortic Calcification in NPP1-/- Mice Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 686 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Schoen and R. J. Levy Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention Ann. Thorac. Surg., March 1, 2005; 79(3): 1072 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Connolly, I. Alferiev, J. N. Clark-Gruel, N. Eidelman, M. Sacks, E. Palmatory, A. Kronsteiner, S. DeFelice, J. Xu, R. Ohri, et al. Triglycidylamine Crosslinking of Porcine Aortic Valve Cusps or Bovine Pericardium Results in Improved Biocompatibility, Biomechanics, and Calcification Resistance: Chemical and Biological Mechanisms Am. J. Pathol., January 1, 2005; 166(1): 1 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nanci, R. M. Wazen, S. F. Zalzal, M. Fortin, H. A. Goldberg, G. K. Hunter, and D.-L. Ghitescu A Tracer Study with Systemically and Locally Administered Dinitrophenylated Osteopontin J. Histochem. Cytochem., December 1, 2004; 52(12): 1591 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood, October 15, 2004; 104(8): 2484 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification Endocr. Rev., August 1, 2004; 25(4): 629 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abedin, Y. Tintut, and L. L. Demer Vascular Calcification: Mechanisms and Clinical Ramifications Arterioscler Thromb Vasc Biol, July 1, 2004; 24(7): 1161 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golledge, M. McCann, S. Mangan, A. Lam, and M. Karan Osteoprotegerin and Osteopontin Are Expressed at High Concentrations Within Symptomatic Carotid Atherosclerosis Stroke, July 1, 2004; 35(7): 1636 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vattikuti and D. A. Towler Osteogenic regulation of vascular calcification: an early perspective Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E686 - E696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Aherrahrou, S. B. Axtner, P. M. Kaczmarek, A. Jurat, S. Korff, L. C. Doehring, D. Weichenhan, H. A. Katus, and B. T. Ivandic A Locus on Chromosome 7 Determines Dramatic Up-Regulation of Osteopontin in Dystrophic Cardiac Calcification in Mice Am. J. Pathol., April 1, 2004; 164(4): 1379 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Shao, S.-L. Cheng, N. Charlton-Kachigian, A. P. Loewy, and D. A. Towler Teriparatide (Human Parathyroid Hormone (1-34)) Inhibits Osteogenic Vascular Calcification in Diabetic Low Density Lipoprotein Receptor-deficient Mice J. Biol. Chem., December 12, 2003; 278(50): 50195 - 50202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Doherty, K. Asotra, L. A. Fitzpatrick, J.-H. Qiao, D. J. Wilkin, R. C. Detrano, C. R. Dunstan, P. K. Shah, and T. B. Rajavashisth Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads PNAS, September 30, 2003; 100(20): 11201 - 11206. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
